In November 2024, 한아원 was a name and a conviction. No revenue. No investors. A team of people who had agreed to work for equity in something that did not yet exist.
By April 2026, the group was generating 3.49 billion won per month across four legal entities — pharmaceutical wholesale, retail pharmacy, a wellness brand, and business automation software. That is a thirty-five-fold increase in eighteen months.
I want to be precise about how this happened, because the number sounds like something that requires explanation, and the explanation is not what most people assume.
What does not explain it
It was not venture capital. We raised a SAFE note for 235,000 dollars and an internal round of approximately 590 million won at a 3.6 billion won post-money valuation. Neither round explains the revenue trajectory.
It was not a single product breakthrough. ODD M-01 is a genuine product that is working in the market. It does not account for the majority of group revenue. The GLP-1 wholesale business does.
It was not luck, in the sense of being in the right place at the right time without effort. We were in the right place because we had built a position in pharmaceutical distribution through eight months of pharmacy operations before the GLP-1 opportunity materialized. The position was built with intention. The opportunity arrived faster than we expected.
What does explain it
The group structure. This is the answer that is hardest to explain because it does not produce the kind of narrative that makes for clean storytelling.
The pharmacy gave us the pharmaceutical distribution relationships. The distribution relationships gave us the position to enter GLP-1 wholesale. The GLP-1 wholesale generated the cash flow that funded the acquisition of 도팜인. The 도팜인 acquisition gave us the scale that made us a credible player in the full supply chain.
Each business made the next business more possible. None of them would have reached the same outcomes independently.
The second thing that explains it
Speed. We are not faster than large incumbents because we are smarter or better capitalized. We are faster because we do not have the institutional structures that make large organizations slow.
Traditional pharmaceutical wholesale takes two to three weeks to evaluate a new distribution opportunity. We evaluated the GLP-1 opportunity in forty-eight hours. Traditional retail pharmacy takes six to twelve months to design and open a new location. We opened our first location in sixty days.
This speed is not permanent. As organizations grow, they develop the institutional habits that make them predictable but slow. The task of the next phase is to build systems that preserve speed without sacrificing reliability.
The thing about rebuilding
People ask me how I rebuilt after 2023. The honest answer is that I did not rebuild the thing I had before. I built something different.
The revenue number is larger. But that is the least interesting part. What is different is the structure of the group — the way each business supports the others — and the clarity I have about what I am actually trying to do.
Before, I was building a company. Now I am building a group that serves a mission. The mission is giving people who have been failed by existing systems — in health, in finance, in access — something that actually works for them.
The group generates 34.9 billion won in annual revenue. The mission is the reason it exists. Both things are true at once.
That is what rebuilding actually looks like.